Free Trial
NASDAQ:ADTX

Aditxt Q4 2025 Earnings Report

Aditxt logo
$0.0032 0.00 (-5.88%)
As of 10/2/2026 03:58 PM Eastern

Aditxt EPS Results

Actual EPS
$315,563.31
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Aditxt Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Aditxt Announcement Details

Quarter
Q4 2025
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Aditxt's next earnings date is estimated for Wednesday, December 2, 2026, based on past reporting schedules.

Conference Call Resources

Aditxt Earnings Headlines

Merck & Co., Inc. (NYSE:MRK) vs. Aditxt (NASDAQ:ADTX) Head to Head Analysis
Aditxt Faces Nasdaq Delisting, Moves Fully to OTC
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - but now he believes he's found something better. This under-the-radar company sits at the intersection of America's two most important industries, including AI, pays massive dividends, and attracted a famous money manager who put 60% of his multi-billion-dollar fund into it. Tilson is revealing the name and ticker symbol completely free - no credit card or email required.tc pixel
Aditxt Stock Dividends | NASDAQ:ADTX | Benzinga
See More Aditxt Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Aditxt? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Aditxt and other key companies, straight to your email.

About Aditxt

Aditxt (NASDAQ:ADTX) is a biotechnology company focused on technologies designed to monitor and reprogram the immune system. The company’s work is aimed at supporting precision medicine by providing detailed information about how an individual’s immune system responds to diseases, vaccines and other biological stimuli.

Aditxt’s core technology platform, AditxtScore, is designed to analyze multiple immune responses simultaneously. Potential applications include infectious disease testing, vaccine-response monitoring, autoimmune disease research and other areas where immune-system profiling may support diagnosis, treatment development or clinical decision-making.

Founded in 2017, Aditxt is headquartered in Mountain View, California. The company has also pursued additional life-sciences initiatives and collaborations intended to expand the use of immune-monitoring and diagnostic technologies. Amro Albanna, a co-founder of the company, has served as its chief executive officer.

View Aditxt Profile